EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials

Mathias Tiedemann Svendsen iD, Sören Möller iD, Steven R Feldman, Klaus Ejner Andersen

Clinical and Experimental Dermatology · 23.12.2025 · 51 (1) · 92-97

DOI: 10.1093/ced/llaf349 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 30.07.2025. Verfasst von Mathias Tiedemann Svendsen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents, Calcitriol, Adrenal Cortex Hormones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Foundation, Odense University Hospital, Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Topical drugs containing corticosteroids are the recommended first-line treatment for mild-to-moderate psoriasis, although the optimal dosage has not been established.

Objectives

To investigate the effect of topical drug application quantity and treatment duration on psoriasis treatment outcomes.

Methods

We conducted a post hoc analysis of two randomized controlled trials investigating 214 patients with psoriasis treated using topical drugs containing corticosteroids and/or calcipotriol for up to 48 weeks. We measured the quantity of topical drugs used during the study period and calculated the mean quantity of applied drugs per 1% affected body surface area (BSA) divided by the number of days in the study period. Improvements in psoriasis were measured using the Lattice System Physician’s Global Assessment (LS-PGA) (where affected BSA is categorized into seven levels) from baseline to final visit. Descriptive results were reported as counts with proportions and as means with normality-based confidence intervals (CIs). Associations were analysed using linear regressions.

Results

Most study participants had a duration of psoriasis > 20 years, moderate psoriasis and no history of receiving systemic psoriasis treatment. They applied a mean of 1.0 g per 1% affected BSA daily (95% CI 0.9–1.2). Daily use of topical drugs for 4 weeks reduced the severity of psoriasis, while extended daily use for up to 48 weeks provided further reductions in disease severity (coefficients –0.30, 95% CI –0.51 to –0.09 and –0.73, 95% CI –1.09 to –0.38, respectively; P = 0.03). Increasing the quantity of topical drugs applied reduced psoriasis severity in a linear manner. Each increase of 1 g of topical drugs applied per 1% affected BSA daily reduced LS-PGA by 0.43 (95% CI 0.24–0.61). Patients who had never received systemic drugs experienced a greater reduction in psoriasis when applying the same mean quantity of topical drugs (coefficient –0.7, 95% CI –1.1 to –0.4) compared with patients with a history of systemic treatment (–0.3, 95% CI –0.5 to –0.1; P = 0.03).

Conclusions

The application of a mean quantity of at least 1.0 g of topical drugs per 1% affected BSA daily is safe and effective and can be used daily until clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDermatologic AgentsCalcitriolAdrenal Cortex HormonesHumansMaleMiddle AgedFemaleAdultSeverity of Illness IndexTreatment OutcomeAgedAdministration, TopicalAdministration, Cutaneous

Substanzen

Dermatologic AgentsCalcitriolcalcipotrieneAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
  • Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark.
  • Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

ORCID-Profile: Mathias Tiedemann Svendsen, Sören Möller

Förderung

  • LEO Foundation
  • Odense University Hospital
  • Memorial Foundation

Zitieren

APA

Svendsen, M. T., Möller, S., Feldman, S. R., & Andersen, K. E. (2025). Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials. Clinical and Experimental Dermatology, 51(1), 92-97. https://doi.org/10.1093/ced/llaf349

Vancouver

Svendsen MT, Möller S, Feldman SR, Andersen KE. Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials. Clinical and Experimental Dermatology. 2025;51(1):92-97. doi:10.1093/ced/llaf349

BibTeX
@article{Svendsen2025,
  author = {Svendsen, Mathias Tiedemann and Möller, Sören and Feldman, Steven R and Andersen, Klaus Ejner},
  title = {Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  volume = {51},
  number = {1},
  pages = {92--97},
  doi = {10.1093/ced/llaf349}
}
Kostenlos starten →